Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29878292 | 0.91 | DRD2 (0.58) | DRD2CA1CA2EPHX2KDM4D | |
| SCHEMBL4735054 | 0.91 | DRD2 (0.58) | DRD2CA1CA2EPHX2KDM4D | |
| SCHEMBL13262741 | 0.84 | CA1 (0.48) | DRD2CA1CA2ACHEEPHX2 | |
| SCHEMBL7399411 | 0.84 | CA1 (0.64) | DRD2CA1CA2ACHEEPHX2 | |
| SCHEMBL4101120 | 0.82 | CA1 (0.47) | DRD2CA1CA2ACHEEPHX2 | |
| SCHEMBL1338041 | 0.82 | CA1 (0.47) | DRD2CA1CA2ACHEEPHX2 | |
| SCHEMBL13263584 | 0.82 | CA1 (0.47) | DRD2CA1CA2ACHEEPHX2 | |
| SCHEMBL17478343 | 0.82 | CA1 (0.47) | DRD2CA1CA2ACHEEPHX2 | |
| SCHEMBL4119861 | 0.82 | CA1 (0.47) | DRD2CA1CA2ACHEEPHX2 | |
| SCHEMBL13189441 | 0.82 | CA1 (0.47) | DRD2CA1CA2ACHEEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217336-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-2632465-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2011-11-10 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| EP-2210890-A1 | Oxadiazole derivatives as S1P1 receptor agonists | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| EP-2202232-A1 | 1,2,4-oxadiazole derivatives and their therapeutic use | Laboratorios Almirall, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | DRD2 1533/4885CA1 4588/4885CA2 3656/4885 |
| US-20110274657-A1 | OXADIAZOLE DERIVATIVES AS S1P1 RECEPTOR ANTAGONISTS | S1PR1, S1PR3, S1PR2 | DRD2 1172/4885CA1 4675/4885CA2 4073/4885 |
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | DRD2 2601/4885CA1 3014/4885CA2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.